Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.

Hiroaki IkesueKenta YamaokaAyako MatsumotoMasaki HirabatakeNobuyuki MuroiToshinari YamasakiMutsushi KawakitaTohru Hashida

Published in: Cancer chemotherapy and pharmacology (2022)

In patients with RCC receiving axitinib, pre-existing proteinuria and non-RAS inhibitor use were significantly associated with grade ≥ 2 proteinuria development. Our preliminary data should be confirmed by further studies.

Keyphrases

renal cell carcinoma
risk factors
metastatic renal cell carcinoma
electronic health record
big data
case control
artificial intelligence
deep learning